Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic renal cell carcinoma (mRCC) presents a significant clinical challenge with limited treatment options.
• Multitargeted tyrosine kinase inhibitors (TKIs) like sunitinib are standard first-line treatments for mRCC.

Observation:

• A 70-year-old male with mRCC experienced disease progression on sunitinib.
• The patient subsequently enrolled in a clinical trial for everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, initially receiving placebo before crossing over to everolimus.

Findings:

• After switching to everolimus, the patient achieved stable disease for 8 weeks, maintained for 28 months.
• The patient ultimately experienced a partial response to long-term everolimus therapy.

Implications:

• This case highlights the potential for long-term benefit with everolimus in mRCC patients progressing on TKI therapy.
• Everolimus may offer a valuable therapeutic option for advanced renal cell carcinoma when used post-TKI treatment, aligning with its approved indication.